Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
A number of other analysts have also issued reports on AXDX. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. BTIG Research lowered Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $33.00.
Accelerate Diagnostics (NASDAQ AXDX) traded up $0.30 on Friday, reaching $23.90. The company’s stock had a trading volume of 364,091 shares, compared to its average volume of 266,404. The firm has a market cap of $1,320.00, a price-to-earnings ratio of -19.92 and a beta of 2.19. Accelerate Diagnostics has a 12-month low of $16.75 and a 12-month high of $30.45.
Several institutional investors have recently bought and sold shares of AXDX. Legal & General Group Plc lifted its position in shares of Accelerate Diagnostics by 31.7% during the 2nd quarter. Legal & General Group Plc now owns 6,748 shares of the medical research company’s stock worth $184,000 after buying an additional 1,625 shares during the period. Cpwm LLC bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $202,000. UBS Asset Management Americas Inc. bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $233,000. Teacher Retirement System of Texas bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $292,000. Finally, Intl Fcstone Inc. bought a new position in shares of Accelerate Diagnostics during the 2nd quarter worth approximately $322,000. Institutional investors and hedge funds own 47.77% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.